

Julien GRASSOT<sup>1\*</sup>, Farah MARZOUKI<sup>1\*</sup>, Roxane HERVE<sup>2</sup>, Magali BECKLER<sup>2</sup>, Luca SEMERANO<sup>2,3</sup>, Natacha BESSIS<sup>2</sup>, Elodie RIVIERE<sup>2,3</sup>, Charles SANSON<sup>1</sup>, Gauthier POULIQUEN<sup>1</sup>, Philippe POULETTY<sup>1</sup> and Marie-Christophe BOISSIER<sup>2,3</sup>  
 1: PK MED, Lyon, France; 2: INSERM U1125, Université Sorbonne Paris Nord, Bobigny, France; 3: Avicenne Hospital, AP-HP, Bobigny, France; \* : co-primary authors



Link to abstract and poster





## BACKGROUND

- Gout is a common type of arthritis, causing excruciatingly painful and disabling flares.
- Gout flares are poorly managed by existing treatments: slow and limited efficacy against pain, combined with safety risks.
- Oral Colchicine (COL) is approved for treating gout flares, but its use and dose levels are limited due to its toxicity.
- We aimed to evaluate the efficacy of a novel intra-articular (IA) combination of sustained release (SR) COL and Ropivacaine (ROPI) (PKM-01)**

## METHODS

- SR COL microspheres are made of already approved biodegradable poly(lactic-co-glycolic acid) (PLGA) polymer
- Carrageenan (CAR) (50 µL CAR 3% injected IA in Sprague Dawley rats) was used to induce ankle or knee hyper acute and severe arthritis
- Controls were PBS or Dexamethasone (DXM) injected in rat joints

## RESULTS



**CONCLUSION**

SR COL + ROPI (PKM-01) demonstrates efficacy in the CAR-induced arthritis model, showing a rapid analgesic effect and significantly preventing joint inflammation and destruction. A Phase II clinical study is planned in gout flares. These results may also highlight potential applications in pseudo-gout and osteoarthritis (OA), where SR COL could be beneficial.

This work has been sponsored by PK MED www.pk-med.com